Feline Cytauxzoonosis

Feline cytauxzoonosis is a severe, often fatal tick-borne protozoal disease of domestic cats caused by Cytauxzoon felis, an apicomplexan hemoparasite [1]. The disease is endemic primarily in the south-central and southeastern United States, with a geographic range that has been expanding in recent decades [2][6]. Bobcats (Lynx rufus) serve as the primary wildlife reservoir, typically sustaining a prolonged subclinical infection; however, in domestic cats the disease progresses rapidly and carries extremely high mortality if left untreated [2]. The complex life cycle of C. felis requires both a tick vector and a mammalian felid host, making exposure to tick-infested environments the principal risk factor [4].

The Pathogen

Cytauxzoon felis is a tick-transmitted, intraerythrocytic apicomplexan protozoan classified among the piroplasmids [2][4]. It has a two-host life cycle requiring a competent tick vector and a felid mammalian host.

Tick Vectors

The lone star tick (Amblyomma americanum) is recognized as the primary and most epidemiologically important vector [4]. Dermacentor variabilis (American dog tick) has also been implicated as a competent vector [2]. The geographic distribution of cytauxzoonosis closely mirrors the habitat range of these tick species, encompassing wooded and brushy areas across the south-central and southeastern United States, with continued geographic expansion [6]. Landscape features such as mixed forest-grassland land cover and certain climatic variables have been identified as environmental risk factors for the disease [6].

Life Cycle and Pathogenesis

C. felis has two distinct intramammalian stages that together drive the pathological process [1][2]:

1. ·

   Schizogony (tissue phase): Following inoculation via tick bite, sporozoites invade mononuclear phagocytic cells — primarily macrophages and monocytes — within the lymphoid tissue, spleen, liver, and lungs. The parasites undergo schizogony (asexual replication) within these cells, forming massive multinucleated schizonts. As parasitized mononuclear cells proliferate and distend with merozoites, they occlude capillaries and small venules throughout the body. This vascular obstruction leads to widespread ischemia, tissue hypoxia, and a systemic inflammatory response, which is primarily responsible for the high case fatality rate [1][2].

2. ·

   Merozoite release and erythrocytic phase: Merozoites released from ruptured schizonts invade circulating erythrocytes, forming small piriform or signet-ring intraerythrocytic forms (piroplasms). While this phase contributes to hemolytic anemia, it is the preceding schizogenous tissue phase — not erythrocyte destruction per se — that causes the most severe and life-threatening pathology [1][2].

Reservoir vs. Domestic Cat

In bobcats, infection results in only a brief, mild febrile illness followed by a persistent, subclinical parasitemia; bobcats therefore act as the enzootic reservoir [2][8]. In domestic cats, the schizogony phase is exaggerated, leading to fulminant disease. Some domestic cats have been documented with subclinical or self-limiting infections, suggesting that host genetic factors and parasite strain variation may influence disease severity [8].

Clinical Suspicion

Cytauxzoonosis should be a primary differential diagnosis in any outdoor cat from an endemic region presenting with acute onset of fever, lethargy, anorexia, and icterus [2][3]. The clinical presentation can mimic hepatic lipidosis and cholangiohepatitis, making diagnostic testing essential to differentiation [3].

Hematological Abnormalities

Complete blood count (CBC) findings characteristically include [2][3]:

• ·Anemia (decreased hematocrit/HCT): Normocytic, normochromic, or regenerative; reflects erythrocyte parasitization and hemolysis
• ·Thrombocytopenia (decreased PLT): A consistent and prominent finding
• ·Leukopenia: Particularly neutropenia and lymphopenia are common; total WBC is frequently low
• ·Identification of intraerythrocytic piroplasms: Small ring-form or signet-ring organisms visible on blood smear (Wright's or Giemsa stain); this is the classic rapid in-clinic diagnostic finding

Serum Biochemical Abnormalities

Biochemical profiles typically reveal [3]:

• ·Elevated total bilirubin (TBIL): Reflecting hemolysis and hepatocellular injury; a prominent finding that may help prioritize cytauxzoonosis over hepatic lipidosis
• ·Elevated ALT: Indicating hepatocellular damage
• ·Hypoalbuminemia (low ALB): Consistent with systemic inflammation and protein loss
• ·Elevated BUN and/or CREA: Indicative of prerenal or renal azotemia due to dehydration and ischemia
• ·Elevated GLOB or hyperglobulinemia: May occur due to inflammatory response
• ·Hypoglycemia: Can occur and may be severe, reflecting hepatic dysfunction and increased metabolic demand

Blood Smear Microscopy

Examination of a thin blood smear remains the cornerstone rapid in-clinic test. Intraerythrocytic piroplasms appear as small (1–2 µm) signet-ring, oval, or tetrad forms within red blood cells [1][2]. The sensitivity of blood smear examination is highest during the acute phase of illness when parasitemia is active.

Fine Needle Aspirates

Cytologic evaluation of aspirates from the spleen, lymph nodes, or liver can reveal the pathognomonic large macrophages distended with developing schizonts, confirming the tissue phase of infection [1][2].

Molecular Diagnostics

Polymerase chain reaction (PCR) assays targeting C. felis DNA offer high sensitivity and specificity and can detect infection even when parasitemia levels are low or blood smear evaluation is equivocal [2][8]. PCR is increasingly used for confirmation and is particularly valuable for detecting subclinical infections in endemic regions [8].

Imaging

Thoracic radiographs may reveal bronchointerstitial pulmonary changes and enlarged or tortuous pulmonary vessels, reflecting vascular obstruction and pulmonary pathology [5].

General Principles

Cytauxzoonosis requires aggressive, intensive supportive care combined with antiprotozoal pharmacotherapy. Early hospitalization and treatment initiation are critical, as clinical deterioration can be rapid [2].

Antiprotozoal Therapy

• ·Atovaquone + Azithromycin: This combination is currently the preferred antiprotozoal protocol and has been associated with improved survival rates compared to older regimens. Atovaquone targets the parasite's mitochondrial electron transport chain, and azithromycin provides synergistic antiprotozoal activity [2].
• ·Imidocarb dipropionate: A historically used antiprotozoal agent; its efficacy against C. felis in the tissue schizont stage is limited, and it has largely been supplanted by the atovaquone/azithromycin protocol [1][2].
• ·Diminazene aceturate: Used in some cases but not widely available in the United States [7].

Supportive Care

Supportive care is a cornerstone of management and includes [1][2][5]:

• ·Intravenous fluid therapy: To correct dehydration, support perfusion, and address azotemia; fluid type and rate must be carefully managed to avoid fluid overload given potential pulmonary compromise
• ·Anticoagulant therapy (heparin): Used to address the hypercoagulable state and vascular obstruction caused by schizont-laden macrophages; unfractionated or low-molecular-weight heparin has been employed
• ·Nutritional support: Assisted feeding (e.g., esophagostomy tube) for prolonged anorexia
• ·Antipyretics / anti-inflammatory agents: Judicious use to control fever and systemic inflammation
• ·Blood transfusions: For cats with severe anemia (low HCT)
• ·Oxygen supplementation: For dyspneic patients
• ·Broad-spectrum antibiotics: Often used empirically given the immunocompromised state and risk of secondary bacterial infection
• ·Analgesics: For cats exhibiting signs of pain or discomfort

Monitoring

Hospitalized cats require close monitoring of temperature, respiratory rate and effort, hematocrit, blood glucose, hydration status, and organ function parameters throughout treatment [2][3].

Historical Mortality

Historically, feline cytauxzoonosis carried a case fatality rate approaching 95–100% in domestic cats without treatment, making it one of the most lethal infectious diseases of cats in endemic regions [1][2]. Death typically occurred within 1–5 days of the onset of clinical signs.

Survival with Modern Treatment

The introduction of the atovaquone + azithromycin protocol, combined with intensive supportive care, has significantly improved outcomes [2]. Reported survival rates with this combination therapy range from approximately 60% or higher in some clinical case series, representing a dramatic improvement over historical outcomes [2]. Despite this improvement, the disease still carries substantial mortality, and some cats die despite aggressive treatment.

Prognostic Indicators

• ·Cats that survive the acute schizogenous vascular obstruction phase and in which merozoite release is controlled have the best chance of recovery [1][2]
• ·Severe hypothermia, profound thrombocytopenia, and respiratory failure are associated with a guarded to grave prognosis [2]
• ·Biochemical severity — including degree of hyperbilirubinemia, azotemia, and hypoglycemia — may correlate with outcome [3]
• ·Cats that recover may develop a chronic, subclinical parasitemia similar to that seen in bobcats and are presumed to be resistant to reinfection [2][8]

Subclinical Infections

A subset of domestic cats in endemic and newly identified endemic regions has been documented with subclinical C. felis infection, surviving without apparent acute disease [8]. Whether these represent a distinct parasite strain, more resistant host genotype, or low-level exposure remains under investigation.

Tick Control

Because no approved vaccine exists for C. felis, tick prevention is the primary and most important preventive strategy [2][6]. Measures include:

• ·Acaricide-based preventive products: Topical or systemic tick prevention products approved for use in cats (e.g., products containing fluralaner or sarolaner where labeled for cats) should be used consistently, especially in cats with outdoor access in endemic regions [2]
• ·Avoidance of tick-infested environments: Limiting or eliminating outdoor access for cats in endemic regions substantially reduces exposure risk, particularly in wooded or brushy areas identified as high-risk habitat [6]
• ·Daily tick checks and prompt tick removal: Manual inspection and removal of ticks before feeding is completed can reduce transmission risk [2]

Environmental and Geographic Awareness

Veterinarians and cat owners in endemic regions — particularly the south-central and southeastern United States, and increasingly the Midwest — should maintain a high index of suspicion for cytauxzoonosis in outdoor cats [2][6][8]. The expanding geographic distribution of vector ticks means that practitioners in traditionally non-endemic areas should also be aware of the disease [3][8].

No Vaccine Available

As of current literature, no commercially available vaccine against Cytauxzoon felis exists, and vaccine development has not been reported in the clinical literature reviewed [2][6]. Prevention therefore relies entirely on tick control and management of exposure risk.

Post-Recovery Carrier Cats

Cats that recover from acute cytauxzoonosis may harbor persistent low-level parasitemia and could theoretically serve as a source for tick acquisition of the parasite. While these cats appear clinically healthy, awareness of their potential reservoir status is warranted [2][8].